...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of pediatric oncology nursing: official journal of the Association of Pediatric Oncology Nurses >Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know
【24h】

Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know

机译：小儿镰状细胞病患者的羟基脲：护士需要知道的

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Sickle cell disease (SCD) is an inherited disorder in which sickled red blood cells occlude the small vessels of the body, reducing oxygen delivery to tissues and ultimately negatively affecting many of the body's major organs. Hydroxyurea has proven beneficial in the treatment of SCD and prevention of disease-related complications. The 2014 guidelines put forth by the National Heart, Lung, and Blood Institute recommend hydroxyurea treatment in infants 9 months and older, children, and adolescents with SCD-SS or SCD-S-0 thalassemia regardless of clinical severity. This is a change from the 2002 guidelines in which hydroxyurea was recommended for adolescents and children with SCD-SS or SCD-S-0 thalassemia with frequent episodes of pain, a history of acute chest syndrome, severe and symptomatic anemia or other severe vaso-occlusive events. Nurses play a critical role in working with patients and families to provide education, guidance, and support to improve compliance to mitigate the long-term effects of SCD.
机译：镰状细胞病（SCD）是一种遗传性疾病，其中镰状红细胞阻塞了人体的小血管，减少了向组织的氧气输送，并最终对人体的许多主要器官造成了负面影响。羟基脲已被证明对治疗SCD和预防疾病相关并发症有益。美国国家心肺血液研究所发布的2014年指南建议对9个月及以上的SCD-SS或SCD-S-0地中海贫血的婴儿，儿童和青少年进行羟基脲治疗，无论其临床严重程度如何。这与2002年的指南有所不同，在2002年的指南中，建议SCD-SS或SCD-S-0地中海贫血的青少年和患有频发性疼痛，急性胸腔综合征，严重和症状性贫血或其他严重血管紧张素血症的儿童阻塞事件。护士在与患者和家属合作提供教育，指导和支持以改善依从性以减轻SCD的长期影响方面发挥着关键作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号